Evidence map›Paper›PMID 25495534›Full record

ArticleHuman gene therapy. Clinical development2014

Imaging cytokine targeting to the tumor/bone microenvironment in vivo.

Jane Ellis, Miriam Falzon, Todd Emrick, Marxa L Figueiredo

Abstract read
In one paragraph

Article in Human gene therapy. Clinical development, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Ligand-Mediated Targeting of Cytokine Interleukin-27 Enhances Its BioactivityMolecular therapy. Methods & clinical development · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jane Ellis1 Department of Pharmacology and Toxicology, University of Texas Medical Branch , Galveston, TX 77555.
Miriam Falzon
Todd Emrick
Marxa L Figueiredo

Funding

Preventing prostate cancer progression by ASC delivery of PEDF and IFNbR21CA153165 · NCI · UNIVERSITY OF TEXAS MED BR GALVESTON · PI FIGUEIREDO, MARXA L · 2012 to 2013
$428k
Pro-peptide gene delivery for treating prostate cancer bone metastasesR21CA179699 · NCI · UNIVERSITY OF TEXAS MED BR GALVESTON · PI FIGUEIREDO, MARXA L · 2013 to 2014
$359k
NCI NIH HHS R21 CA153165NCI NIH HHS R21 CA179699NCI NIH HHS R21CA179699
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Tumor MicroenvironmentAmino Acid SequenceAnimalsBone NeoplasmsCytokinesGenes, ReporterLuciferases, FireflyMaleMiceMolecular Sequence DataOptical ImagingProstatic NeoplasmsWhole Body ImagingCytokinesLuciferases, Firefly

Identifiers

PMID25495534
PMCPMC4346606

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.